Ranjana H. Advani mostly deals with Internal medicine, Oncology, Lymphoma, Surgery and Immunology. Her Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology. She has researched Oncology in several fields, including Clinical trial, Phases of clinical research, Bendamustine, Rituximab and Retrospective cohort study.
Her Lymphoma study combines topics in areas such as Cancer, Cancer research and Radiation therapy. Ranjana H. Advani works mostly in the field of Surgery, limiting it down to concerns involving Cohort and, occasionally, Risk factor, Chemoradiotherapy, Multivariate analysis and Pleural effusion. Her Immunology research incorporates elements of Agonist, Biopsy and Intensive care medicine.
Her primary areas of investigation include Internal medicine, Oncology, Lymphoma, Rituximab and Surgery. Ranjana H. Advani works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Tolerability. Her Oncology research is multidisciplinary, incorporating perspectives in Refractory, Radiation therapy, Immunology and Hodgkin lymphoma.
Her Lymphoma research includes elements of Cancer, BCL6 and Transplantation. As part of one scientific family, Ranjana H. Advani deals mainly with the area of Rituximab, narrowing it down to issues related to the Vincristine, and often CHOP. Her work deals with themes such as Clinical endpoint, Ibrutinib and Mantle cell lymphoma, which intersect with Phases of clinical research.
The scientist’s investigation covers issues in Internal medicine, Oncology, Lymphoma, Brentuximab vedotin and Hodgkin lymphoma. Her research combines Gastroenterology and Internal medicine. Her Oncology research includes themes of Blockade, Follicular lymphoma and Phases of clinical research.
Her studies deal with areas such as Prospective cohort study, BCL6 and Transplantation as well as Lymphoma. Within one scientific family, she focuses on topics pertaining to Nivolumab under Brentuximab vedotin, and may sometimes address concerns connected to Ipilimumab. Her Hodgkin lymphoma study integrates concerns from other disciplines, such as Advanced stage, Stanford V, Cohort and MEDLINE.
Ranjana H. Advani focuses on Internal medicine, Oncology, Lymphoma, Brentuximab vedotin and Chemotherapy. Her study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology. Her Gastroenterology study combines topics from a wide range of disciplines, such as Febrile neutropenia, Neutropenia and Tolerability, Adverse effect.
The study incorporates disciplines such as Survival rate, Prospective cohort study, Clinical trial and Disease in addition to Oncology. Her work carried out in the field of Lymphoma brings together such families of science as Blockade and Cancer research. The concepts of her Brentuximab vedotin study are interwoven with issues in Chlorambucil, Nivolumab, Chemotherapy regimen and Doxorubicin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow;Elias Campo;Stefano A. Pileri;Nancy Lee Harris.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang;Simon Rule;Peter Martin;Andre Goy.
The New England Journal of Medicine (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani;Joseph J. Buggy;Jeff P. Sharman;Sonali M. Smith.
Journal of Clinical Oncology (2013)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro;Ranjana Advani;Pauline Brice;Nancy L. Bartlett.
Journal of Clinical Oncology (2012)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson;Ryan M. Young;Roland Schmitz;Yandan Yang.
Nature Medicine (2015)
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Steven P. Treon;Christina K. Tripsas;Kirsten Meid;Diane Warren.
The New England Journal of Medicine (2015)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G.M. Roemer;Ranjana H. Advani;Azra H. Ligon;Yasodha Natkunam.
Journal of Clinical Oncology (2016)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Ranjana Advani;Ian Flinn;Leslie Popplewell;Andres Forero.
The New England Journal of Medicine (2018)
Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Ashley A. Powell;AmirAli H. Talasaz;Haiyu Zhang;Marc A. Coram.
PLOS ONE (2012)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody;Weiyun Z. Ai;Debra K. Czerwinski;James A. Torchia.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: